The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recently, President Trump signed a “most-favored nation” executive order on drug prices with a claim that it would force pharmaceutical companies to lower U.S. prescription costs to match those abroad ...

Over a weekend in late September, the team of Pfizer officials working with the Trump administration on drug prices got a message: Clear your schedules. Negotiations were reaching a tipping point. CEO ...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...

Pfizer announced yesterday it was settling an epic legal battle with the Indian drugmaker Ranbaxy Laboratories that will keep generic versions of the best-selling cholesterol medicine Lipitor off the ...

Pfizer recently filed at least seven lawsuits in federal court seeking to enjoin multiple multinational pharmaceutical companies from selling a generic version of its medication, Nurtec, which is used ...

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying more ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.